The U.S. Food and Drug Administration has announced it met its first-year targets under a 2025 roadmap designed to reduce reliance on animal testing in preclinical drug development, marking a significant step in modernizing how medicines are evaluated for safety before human trials.
One year after releasing the Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the FDA confirmed it has launched multiple initiatives to replace animal-based methods with human-relevant alternatives such as organ-on-a-chip systems, computational models, and in vitro assays derived from human cells.
According to the agency’s progress report, these efforts aim to improve the predictiveness of drug safety testing although addressing the high failure rate of candidates that pass animal studies but fail in human trials due to toxicity or lack of efficacy—a problem affecting more than 90% of experimental drugs.
FDA Commissioner Marty Makary emphasized that the shift is not only scientifically warranted but similarly economically beneficial, stating that reducing ineffective animal testing could lower research and development costs and ultimately reduce drug prices for consumers.
The roadmap specifically targets areas where non-animal methods have demonstrated equivalent or superior predictive value, including endotoxin testing traditionally derived from horseshoe crabs—a process that could spare over one million animals annually if fully replaced by synthetic alternatives.
the FDA has released draft guidance aimed at reducing or eliminating the use of nonhuman primates in the development of monoclonal antibodies, a class of drugs widely used in treating cancer, autoimmune diseases, and infectious conditions.
These actions are part of a broader initiative under the New Approach Methodologies (NAMs) framework, which the FDA defines as innovative testing strategies that enhance the assessment of drug safety, efficacy, and quality while minimizing animal use.
The agency highlights that NAMs—including AI-driven toxicity prediction models, microfluidic organ chips, and real-world data analytics—offer a more accurate reflection of human biology than conventional animal models, thereby improving the success rate of clinical trials.
To support adoption, the FDA has expanded several existing programs, such as the Innovative Science and Technology Approaches for New Drugs (ISTAND) initiative and the Drug Development Tool (DDT) qualification process, which help evaluate and gain regulatory acceptance for novel testing methods.
Through Critical Path Innovation Meetings (CPIM) and INTERACT forums, the agency is also fostering early collaboration with developers to identify opportunities where NAMs can be integrated into investigational new drug (IND) applications.
Officials note that while full replacement of animal testing remains a long-term goal, the current focus is on phased implementation where scientifically validated alternatives exist, ensuring patient safety is not compromised during the transition.
The FDA’s Year One Progress and the Path Forward report, released alongside the announcement, details milestones achieved since April 2025 and outlines upcoming priorities, including refining guidance documents and expanding public access to NAMs resources through its official website.
Stakeholders in the pharmaceutical industry, animal welfare organizations, and patient advocacy groups have been engaged throughout the process, with the FDA stating that feedback has helped shape practical, implementable pathways for innovation.
As part of its commitment to transparency, the agency continues to update its NAMs Activities page with information on selected guidance documents, upcoming meetings, and qualification opportunities for new methodologies.
Looking ahead, the FDA plans to build on this foundation by pursuing additional policy updates and scientific collaborations aimed at further reducing unnecessary animal use while accelerating the delivery of safer, more effective treatments to patients.
For ongoing updates, readers can refer to the FDA’s official announcements page or subscribe to email alerts from the Center for Drug Evaluation and Research (CDER).
We welcome your thoughts on this development. Share your perspective in the comments below or join the conversation on social media using the hashtag #FutureOfDrugTesting.